54 results
8-K
EX-99.1
PRTA
Prothena Corporation plc
8 May 24
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
4:09pm
with early Alzheimer’s disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb
Strengthened leadership position in the amyloidosis
8-K
EX-99.1
PRTA
Prothena Corporation plc
15 Feb 24
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
4:09pm
-986446 (formerly PRX005), an anti-tau antibody, data supports moving into a Phase 2 clinical trial by partner Bristol Myers Squibb
Strengthened leadership … continue to grow our leadership at Prothena, we also appointed the founding, former Director of the FDA CDER Office of Neuroscience, Dr. Billy Dunn, to our
8-K
EX-99.1
lofcq9dp2dwp
5 May 22
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
12:00am
8-K
EX-99.1
xzsnvxd
12 Feb 20
Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
4:13pm
8-K
EX-99.1
n4b3 j9jc21
6 Aug 19
Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
4:08pm
8-K
EX-99.1
gutu97fezs 1j77bk
7 Aug 18
Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update
12:00am